Ceribell (CBLL) Short-term Investments (2025 - 2026)
Ceribell (CBLL) posted Short-term Investments of $95.9 million for Q1 2026, down 19.24% on a QoQ basis from $118.8 million in Q4 2025, and up 226.97% year-over-year from $29.3 million in Q1 2025.
Ceribell (CBLL) Short-term Investments (2025 - 2026) Analysis & Trends
Ceribell's Short-term Investments history runs 2 years deep, the most recent figure standing at $95.9 million for Q1 2026.
- Quarterly Short-term Investments rose 226.97% year-over-year to $95.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.9 million (up 226.97% YoY) and the FY2025 annual result came in at $118.8 million, changed N/A from the prior year.
- Short-term Investments was $95.9 million for Q1 2026 at Ceribell, down from $118.8 million in the prior quarter.
- Across five years, Short-term Investments topped out at $144.8 million in Q3 2025 and bottomed at $29.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Ceribell | 613.16 Mn | 471.97 Mn | 23.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.93 Mn |
| Dec 31, 2025 | 118.79 Mn |
| Sep 30, 2025 | 144.80 Mn |
| Jun 30, 2025 | 137.29 Mn |
| Mar 31, 2025 | 29.34 Mn |